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Abstract
Background:  The parallel plate flow chamber has become a mainstay for examination of
leukocytes under physiologic flow conditions. Several design modifications have occurred over the
years, yet a comparison of these different designs has not been performed. In addition, the reagent
requirements of many designs prohibit the study of rare leukocyte populations and require large
amounts of reagents.
Results:  In this study, we evaluate modifications to a newer parallel plate flow chamber design in
comparison to the original parallel plate flow chamber described by Lawrence et al. We show that
modifications in the chamber size, internal tubing diameters, injection valves, and a recirculation
design may dramatically reduce the cellular and reagent requirements without altering
measurements.
Conclusions:  These modifications are simple and easily implemented so that study of rare
leukocyte subsets using scarce or expensive reagents can occur.
Background
Localization of leukocytes to tissue sites is a critical part
of infectious, inflammatory or immune responses [1,2].
Emigration of leukocytes from blood into tissue requires
a complex array of molecular and cellular events between
the flowing leukocyte and endothelium lining the blood
vessel wall. Development of the parallel plate flow cham-
ber that simulates the conditions of physiologic flow has
been an important tool for dissecting the molecular
events occurring between flowing leukocytes and en-
dothelium [3–13].
One of the first parallel plate flow chamber described to
study neutrophil adhesion to endothelium was described
in 1987 by Lawrence et al [7]. Initially, several investiga-
tors produced chambers identical to or very similar to
this design, and over the years this initial design has been
the most widely used [8]. This design allowed for study
of leukocyte-endothelial interaction from a top-down
view and under laminar flow that occurs in the post-cap-
illary venules, the physiologically relevant site for most
leukocyte emigration. Design modifications have also
been made that allow for pulsatile flow, a simulation of
larger vessel blood flow, as well as lateral viewing that
can give more detailed morphologic information [11,12].
Agarose-cast vessels and glass capillary flow chambers
have also been described [12,14,15]. In spite of the large
number of scientifically important observations that
have been made with this technology, these chambers
have at least two weaknesses: 1) Significant numbers of
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leukocytes are required, making study of rare leukocyte
populations such as basophils or some lymphocyte sub-
sets difficult, and 2) Large amounts of inhibitors are
needed to study their effects, limiting the use of the par-
allel plate as a tool for drug discovery. More recently, a
commercially-produced flow chamber (GlycoTech,
Rockville, MD) is available that potentially overcomes
these weaknesses, since it is considerably smaller than
the initial chamber produced by Lawrence et al [7].
In this study we were interested in comparing the rea-
gent and cellular requirements of the newer GlycoTech
chamber with different modifications to the chamber de-
scribed by Lawrence [7]. In addition, we wished to test
modifications in tubing and pumps in order to optimize
the architecture of the flow chambers for study of rare
leukocyte populations and small molecule antagonists.
Results and Discussion
Comparison of volume and cellular requirements for dif-
ferent parallel plate flow chamber configurations
We empirically determined the volume needs for each
chamber design and modification by measuring the vol-
ume needed to fill the chamber, tubing, and other com-
ponents. A comparison of the volume and cellular
requirements for each parallel plate flow chamber con-
figuration is summarized in Table 1. We compared the
potential capabilities of three chamber designs, the orig-
inal chamber designed by Lawrence [7] ("classic" cham-
ber), the single pass GlycoTech design (Product 31–001),
and a recirculating design using the GlycoTech chamber
(Fig. 1). In order to assess the potential cellular require-
ments for an experiment, we assumed usage of standard
isolation techniques of blood leukocytes with venipuc-
ture volumes that we and others employ for these exper-
iments [6,13,16,17], which are 30 ml, 100 ml, and 100 ml
for neutrophils, eosinophils, and basophils, respectively.
Neutrophils, eosinophils and basophils are at concentra-
tion ranges of 1800–7000/µl, 0–300/µl, and 0–100/µl,
respectively, in normal adults [18]. Accordingly, the total
cells yielded from these preparations are typically 3 ×
107, 2 ×  106, and 6 ×  105 leukocytes per preparation of
neutrophils, eosinophils, or basophils, respectively. Fur-
thermore, one of the disadvantages of the GlycoTech
chamber is that it does not have injection ports for stud-
ying the rapid effects of soluble substances on leukocyte
behavior. To circumvent this problem, we added a stop-
cock valve to allow for reagent injection (Fig. 1C). This
design with the stopcock was used in the calculations be-
low.
We next calculated the number of cells that would be re-
quired for the two most common usages of a parallel
plate flow chamber; 1) a standard shear curve (i.e.
number of cells attached to a surface versus a range of
shear forces) and 2) a constant shear perfusion experi-
ment in which the number of attached cells is deter-
mined over a 10 min period. In order to obtain a
significant number of attached cells during the experi-
ment, we assumed that cells would be used at a concen-
tration of 1 ×  106/ml as is commonly practiced. Using
standard tubing (0.062" I.D, internal diameter) there are
significant differences in the volume and cells needed for
an experiment using the three chamber configurations.
The classic and single pass GlycoTech chamber needed 1
×  107 versus 2.4 ×  106 cells to produce a shear curve. One
of the weaknesses of the re-circulating parallel plate us-
ing a Harvard Apparatus peristaltic pump is that the
pump rate cannot be changed without stopping the
pump. Thus, the reciculating design in Fig. 1D cannot be
used to produce shear curves. Likewise, there are signif-
icant differences in the cellular and volume needs for a
constant shear experiment between the classic, single
pass GlycoTech, and recirculation chambers (1.2 ×  107,
2.2 ×  106, and 4.1 ×  106 cells respectively).
Tubing diameter may also dramatically impact the total
volume and cells required per experiment. We examined
the dead volume and total cellular requirements using
the standard 0.062" ID as well as 0.02" ID and 0.01" ID
tubing. We did not use ID less than 0.01" ID (254 µm)
since neutrophil diameters vary from 7–15 µm, and we
wished to have ample diameter for cell passage. Further-
more, post-capillary venules, the physiologically relevant
site of leukocyte extravasation, have diameters of 30–80
µm [19]. Finally, technical issues occurred with 0.01" ID
(see below). Narrower internal tubing diameters resulted
in a 66–83 % reduction in cell or volume requirements.
Therefore, an increase in number of experiments could
be performed per cell preparation, and the need for rea-
gents whether they be soluble factors, monoclonal anti-
bodies, or small molecule antagonists would also be
reduced proportionately with smaller volumes.
Reduction in the proportion of dead volume to total vol-
ume per experiment also contributes to the reduction in
cells and reagents. The dead volume is dramatically re-
duced with the reduction of the internal diameter of the
tubing regardless of chamber design (Table 1). One of the
principal reasons of regeant and cell waste is the dead
volume, since dead volume constitutes from 6–100% of
the total volume per experiment (depending on the
chamber configuration, see Table 1). Since the dead vol-
ume is reduced in addition to the total volume with either
the single pass or recirculating GlycoTech chamber de-
sign in comparison to the classic chamber, there is signif-
icant reduction in the amount of reagent or cells needed
for each experiment.BMC Immunology 2001, 2:9 http://www.biomedcentral.com/1471-2172/2/9
The length of time of an experiment is also important
consideration in the comparison of the single pass Glyco-
Tech to recirculating design in terms of reagent use. The
GlycoTech chamber requires 66–83% less cells or rea-
gents in comparison to the GlycoTech single pass in a 10
min constant shear experiment. However, if 3 min exper-
iments with 0.062" ID tubing were performed, which
have been reported [13], then the recirculating chamber
requires 15% more total volume than the classic chamber
and 639% more volume than the single pass GlycoTech
chamber. Thus, since the single pass chamber requires
increasing reagents with time, the requirements may be
smaller with the re-circulating configuration depending
on the length of experiment.
Validation
To verify the performance of the single pass GlycoTech
and re-circulating flow chamber, measurements of leu-
kocyte adhesion made with these chambers were com-
pared to those of the classic chamber. Several standard
measurements can be made with a parallel plate flow
chamber, including the total number of attached cells,
the number of rolling cells, the number of firmly arrested
cells, and the rolling velocity. We performed experiments
that measured each of these quantities and compared the
precision of the measurements among each parallel plate
flow chamber design.
We first examined the number of flowing neutrophils
that attached to EC monolayers in both the classic and
GlycoTech single pass flow chambers over a range of
Table 1: Characteristics of different parallel plate flow chambers
Classic GlycoTech
Single-Pass Single-Pass Re-circulation
Chamber Chamber Chamber
Cells Needed For
Shear Curve
0.062" I.D. 1 ×  107 cells 2.4 ×  106 cells N/A
(5,000 ul) (1,175 ul)
0.02" I.D. 9.9 ×  106 cells 2 ×  106 cells N/A
(4,950 ul) (1,000 ul)
Leucocytes Per
Constant Shear
Experiment*
0.062" I.D. 1.2 ×  107 cells 2.2 ×  106 cells 4.1 ×  106 cells
(6,000 ul) (1,075 ul) (2,070 ul)
0.02" I.D. 9.9 ×  106 cells 1.8 ×  106 cells 1.7 ×  106 cells
(4,950 ul) (900 ul) (850 ul)
Dead Volume
0.062" I.D. 1,500 ul 225 ul 2,070 ul
0.04" I.D. 820 ul 110 ul 1,290 ul
0.02" I.D. 450 ul 50 ul 850 ul
0.01" I.D. 360 ul 35 ul 740 ul
Number Of Constant
Shear Experiments
Per Cell
Preparation*
Neutrophil 21 5 2 3
Eosinophil 0 4 5
Basophil 0 2 4
Reduction In Cell/
mAb/Reagent Use
0.062" I.D. 0% 82% 66%
0.02" I.D. 0% 82% 83%
* Number of experimental conditions calculated assuming 0.02" I.D. for the improved chamber and 0.062" I.D. for the classic chamber. I.D., internal 
diameter; N/A, not applicable, see text for details. Approximate cell number per preparation is 3 ×  107 neutrophils, 2 ×  106 eosinophils, and 6 ×  105 
basophils per preparation. Dead volume refers to the entire fluid volume external to the flow path.BMC Immunology 2001, 2:9 http://www.biomedcentral.com/1471-2172/2/9
shear stress. (Fig 2A) The range of shear stress was cho-
sen to recapitulate those in the post-capillary venules
(0.5–5 dynes/cm2). No statistically significant differenc-
es were seen in terms of the number of cells that attached
to activated endothelium over the range of shear stresses
examined.
We next examined whether the number of rolling and
firmly adhered cells was quantified similarly. We per-
fused neutrophils over a monolayer of activated EC at 1.5
dynes/cm2 for 10 mins. Each min we determined the
number of rolling and firmly adhered cells in the micro-
scope field using each of the three chambers (Fig. 1B). No
statistically significant differences were seen between
Figure 1
Schematic of parallel plate flow chamber configurations. (A) The parallel plate flow chamber as described by Lawrence et al [7].
(B) The parallel plate available from Glycotech, (C) Schematic of the single pass chamber with value in place for injection of
cells or soluble reagents, (D) Schematic for recirculating system with parallel plate flow chamber.BMC Immunology 2001, 2:9 http://www.biomedcentral.com/1471-2172/2/9
the classic, single pass GlycoTech or recirculating de-
signs. These experiments were performed with 0.02" ID
tubing, since similar experiments with 0.01" ID tubing
had bubbles in the line that stripped the neutrophils off
the EC surface periodically (data not shown). This oc-
curred even after de-gasing the perfusion buffer over-
night. Although not proven, we think this is likely due to
small difference between the ID of the tubing and the
connecting ports that allows for slow accumulation of
bubbles that periodically release, flowing over, and de-
stroying the monolayer.
Finally, we calculated the rolling velocity in the different
chambers (Table 2). Neutrophils were perfused over cell
monolayers expression E- or P-selectin and the rolling
velocities calculated. The selectins are a family of mole-
cules on which neutrophils will roll but not firmly adhere
[20]. Table 2 shows that significant differences in rolling
velocities of neutrophils were seen on E- versus P-selec-
tin coated surfaces in agreement with previous observa-
tions. However, statistically significant differences in the
rolling velocities on cellular surfaces with E- or P-selec-
tin were not observed regardless of flow chamber design.
Although the recirculation design may suggest that the
neutrophils pass over the cell monolayer several times,
the volumes and perfusion rates suggest otherwise. For
instance, the recirculating design has a dead volume of
850 µl. In a 10 min experiment at 1.5 dynes/cm2, fluid is
perfused at 75 µl/min for a total of 750 µl or only 88% of
the volume, suggesting that the flowing neutrophils do
not pass over the monolayers more than once. Finally, al-
though gap height of the chamber may also be varied to
reduce the volumes, we employed the narrowest gasket
currently available for the Glycotech chamber (127 µm).
Conclusions
We have shown that alterations in the configuration of
flow chambers can dramatically reduce reagent and cel-
Figure 2
Comparison of measurements in the 3 parallel plate flow chamber configurations. (A) Shear curves generated by perfusing neu-
trophils over activated with LPS (squares) or unactivated (triangles) EC using the classic (closed triangle and square) or single
pass (open triangle or square) Glycotech chambers. The experiment was performed as described in the material and methods
section. (B) Constant shear experiments comparing the three different chamber configurations as described in material and
methods. Neutrophils were perfused over activated endothelium in either the classic (B1), single pass Glycotech (B2), or recir-
culation chambers (B3). The number of rolling (black bars) and arrested (clear bars) cells were determined each minute. S.D. is
indicated by bars. S.D. bars directed up represent S.D. for rolling cells, and S.D. bars directed down represent S.D. for firm
cells; n = 3.
Table 2: Rolling velocities of neutrophils on E- and P-selectin*
Chamber E-selectin P-selectin
Classic 2.7 um/sec (0.8) 9.0 um/sec (2.3)
Single Pass GlycoTech 3.0 um/sec (0.7) 10.2 um/sec (2.3)
Recirculation Glyco-
Tech
3.8 um/sec (1.3) 9.7 um/sec (2.0)
*Rolling velocities determined as described in Material and Methods on 
CHO cells expressing human E- or P-selectin. S.D. is indicated in pa-
renthesis.BMC Immunology 2001, 2:9 http://www.biomedcentral.com/1471-2172/2/9
lular requirements. These modifications do not adverse-
ly effect quantification. In the past, it has not been
feasible to study cell populations that were represented
at less than 2% of peripheral blood leukocytes such as ba-
sophils, eosinophils, or some lymphocyte subsets. For in-
stance, 100 ml of blood yields only ~6 ×  105 basophils
[17]. This number of basophils was not sufficient for
studies in the classic chamber. With these modifications
in this report, 4 experiments can be performed Reduc-
tions in reagent requirements proportional to those of
cellular needs also occur in with the modifications em-
ployed in this report, since the modifications primarily
decrease volume requirements. We have also configured
an injection port in the single pass GlycoTech chamber
configuration, allowing for observation of the rapid ef-
fects of use of soluble factors. Thus, small molecules such
as chemokines, peptides or non-peptide organic com-
pounds that previously would be prohibitively expensive
to study can now be studied. For instance, 10 mg of a de-
capeptide commercially produced for approximately
$1000.00 and used at a concentration of 1 mM would re-
quire 6.6 mg peptide/experiment at a approximate cost
of $660/experiment while the recirculating chamber
with 0.02" ID tubing requires 0.94 mg at cost of $93.50/
experiment, making large number of experiments af-
fordable.
Material and Methods
Neutrophil isolation and cell culture
Human umbilical vein endothelial cell (EC) cultures
were purchased (Clontech, Palo Alto, CA) and main-
tained at 30–80% confluency to ensure high viability.
Chinese Hamster Ovary (CHO) cells expressing human
E- or P-selectin have been previously described [6,13].
Cells were incubated at 37°C in an air/5% CO2 atmos-
phere. Neutrophils were isolated as previously described
in detail from peripheral blood isolated by venipuncture
from normal donors [6,13].
Parallel plate flow chamber apparatus configuration and 
modifications
Two flow chambers with parallel plate geometry were
used (Fig. 1A and 1B). Both flow chambers consist of: (1)
base plate with an entrance and exit port through which
cells and media are perfused, (2) a glass or plastic slide
plate on which the substrate or cellular monolayer is
placed, (3) a gasket that controls the chamber diameter,
and (4) a vaccum outlet so that the apparatus can be held
in place. The sizes of these chambers and their compo-
nents are summarized in Fig. 1. The first parallel plate
had the identical dimensions as described by Lawrence
et al [7] and was kindly provided by Dr. Lawrence (Uni-
versity of Virginia). The second chamber was purchased
from GlycoTech (Product number 31–001, Rockville,
MD). The GlycoTech chamber was tested in two different
configurations, single-pass configuration and a re-circu-
lating configuration. A syringe pump (Harvard Appara-
tus, Model 22, Cambridge, MA) was employed in the
single pass configuration and a peristaltic pump (Har-
vard Apparatus, Model 66) was used in the recirculating
configuration. Internal tubing diameter is indicated in
the text. The components of each configuration were set
up to minimize tubing, and the volume requirements de-
termined empirically by measuring the volume needed
to fill the apparatus. A chamber was placed on the stage
of an inverted microscope (Olympus, NY). A CCD camera
(Vicon VC240, Albuquerque, NM) enabled recording of
all events in the video field by a Toshiba KV-7168A re-
corder (ADI, Albuquerque, NM). The recorded images
were analyzed using NIH Image 1.61 software (available
via download at  [http:rsb.info.nih.gov/nih-image] ).
Parallel plate flow chamber analysis
Cellular events in the parallel plate flow chamber were
enumerated as previously described [6,16]. Briefly, Neu-
trophils are perfused over EC or CHO cell monolayers at
defined shear forces as indicated in text in the parallel
plate flow chamber. EC are treated with media alone or
media containing a potent activator, lipopolysaccharide
(LPS) at 5 µg/ml for 4 h, washed, and placed in a parallel
plate flow chamber.
The entire period of leukocyte perfusion was videotaped
under phase-contrast microscopy. All experiments were
recorded with a CCD video camera and recorder. Video-
taped data frames were digitized for data analysis. Four
quantities were measured in the analysis: the total
number of accumulated cells, the number of rolling cells,
the number of firmly arrested cells, and the rolling veloc-
ity. The total number of accumulated cells was deter-
mined from videotape at each min for 10 min by analysis
of 8–10 random fields (20X phase-contrast objective).
Leukocytes were considered firmly adherent after 15 s of
stable contact with the monolayer. Rolling cells were eas-
ily visualized since they traveled more slowly than free-
flowing cells. Rolling velocities were measured for all
cells in two to five fields of view for each experiment. Re-
sults are presented as averages. Images were recorded on
a time-lapse videocassette recorder at real time and
played back at 9-fold slower speed. The tape was paused
to mark the location of cells, and the distance that the
center of individual cells moved was measured 2 to 4 s
later.
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